Agoyu integrated its AI moving quote tool into select Realtor.com rental and for-sale listings. Users record a short video of belongings, and the AI estimates weight and volume to deliver real time ...

Saves labware, resources, and time Preserves frequently finite FFPE sample Increases the accuracy of tumor profiling by mitigating the bias caused by FFPE sample variability Compared to parallel or ...

Generate Biomedicines, Inc. is a clinical-stage biotechnology company focused on using artificial intelligence and machine learning to create protein-based medicines. The company operates in the ...

AI has taken the world by storm over the last few years, with millions of users writing prompts on platforms like ChatGPT to generate content, images, and yes videos. Still, some of these platforms ...

“Do the savings at Costco justify the price of driving out there? Or should I pay more at one of the grocery stores within walking distance?” DAKOTA WYLDE, who lost his job as a contractor at the ...

AI video generators help you turn your prompts into believable videos, complete with audio. We've tested all the top services to help you choose the one that does the best job with the fewest tweaks.

We've tested the top AI image generation apps to help you find the one that produces the best results for the lowest price. I’ve been writing about consumer technology and video games for more than a ...

Rebar, a startup building an AI operating system for commercial HVAC suppliers, has raised $14 million in a Series A funding round, it tells Crunchbase News exclusively. Founded in October 2024, Rebar ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...